Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 1998, p. 1074-1080, Vol. 36, No. 4
Department of Medicine1
Departments of Pediatrics and Molecular Genetics & Microbiology,4 University of Medicine and
Dentistry of New Jersey-Robert Wood Johnson Medical School, New
Brunswick, New Jersey;
Center for Advanced Biotechnology and
Medicine, University of Medicine and Dentistry of New Jersey, Robert
Wood Johnson Medical School and Rutgers University, Piscataway, New
Jersey2; and
Marshfield Laboratories,
Marshfield, Wisconsin3
Received 14 August 1997/Returned for modification 8 October
1997/Accepted 8 December 1997
We previously reported on the efficacy of the enzyme-linked
immunoglobulin M capture immune complex (IC) biotinylated antigen assay
(EMIBA) for the seroconfirmation of early Lyme disease and active
infection with Borrelia burgdorferi. In earlier work we identified non-cross-reacting epitopes of a number of B. burgdorferi proteins, including flagellin. We now report on an
improvement in the performance of EMIBA with the addition of a
biotinylated form of a synthetic non-cross-reacting immunodominant
flagellin peptide to the biotinylated B. burgdorferi B31
sonicate antigen source with the avidin-biotinylated peroxidase complex
detection system used in our recently developed indirect IgM-capture
immune complex-based assay (EMIBA). As in our previous studies, the
enzyme-linked immunosorbent assay (ELISA) reactivities of antibodies
liberated from circulating ICs (by EMIBA) were compared with those of
antibodies in unprocessed serum (antibodies found free in the serum,
thus as an IgM-capture ELISA, but not EMIBA, because the antibodies were not liberated from ICs), the sample usually used in standard ELISAs and Western blot assays. The addition of the flagellin epitope
enhanced the ELISA signal obtained with untreated sera from many Lyme
disease patients but not from healthy controls. In tests with both free
antibodies and ICs, with or without the addition of the flagellin
epitope to the sonicate, we found the most advantageous combination was
IC as the source of antibodies and sonicate plus the flagellin epitope
as the antigen. In a blinded study of sera obtained from patients with
early and later-phase Lyme disease, EMIBA with the enhanced antigenic
preparation compared favorably with other serologic assays, especially
for the confirmation of early disease.
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Immunoglobulin M Capture Assay for Serologic
Confirmation of Early Lyme Disease: Analysis of Immune Complexes with
Biotinylated Borrelia burgdorferi Sonicate Enhanced with
Flagellin Peptide Epitope
*
Corresponding author. Mailing address: 1 Robert Wood
Johnson Place MEB 484, New Brunswick, NJ 08903-0019. Phone: (732)
235-7704. Fax: (732) 235-7238. E-mail: sigallh{at}umdnj.edu.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|